根据最新提交至美国证券交易委员会（SEC）的文件显示，营养补充品公司寰泰生技（Mannatech Inc）决定不再续签其首席财务官詹姆斯·克拉维霍（James Clavijo）的雇佣协议，该协议将于2026年6月30日到期。
这一重大人事变动意味着克拉维霍在现任合约期满后将不再担任公司CFO职务。作为上市公司关键高管，其去留往往引发市场对企管策略与财务稳定性的关注。
尽管文件未详细说明不再续约的具体原因，但此类高管合约决策通常涉及公司战略调整、管理层重组或个人职业规划等多重因素。投资者或将密切关注后续人事安排及对公司运营的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.